跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 2026-10-08AI 评分55

Endeavor BioMedicines 称其 IPF 在研药物中期试验成功,并宣称可逆转疾病

Endeavor notches major mid-stage trial win, says IPF drug can reverse disease

AI 导读

Endeavor BioMedicines 称其在研的慢性肺部疾病(IPF)药物在一项中期临床试验中取得成功,并宣称该药具有逆转疾病的潜力。该表述来自公司方面,原文可见部分未给出具体疗效数据、样本量或试验设计细节。原文为付费内容,正文仅显示开头段落。

正文

En­deav­or Bio­Med­i­cines said its treat­ment for a chron­ic lung dis­ease suc­ceed­ed in a mid-stage test, claim­ing the drug had the po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news